Analysis of the impact of handling and culture on the expansion and functionality of NK cells

Front Immunol. 2023 Aug 11:14:1225549. doi: 10.3389/fimmu.2023.1225549. eCollection 2023.

Abstract

Natural killer (NK) cells are lymphocytes of the innate immune system that play a key role in the elimination of tumor and virus-infected cells. Unlike T cells, NK cell activation is governed by their direct interaction with target cells via the inhibitory and activating receptors present on their cytoplasmic membrane. The simplicity of this activation mechanism has allowed the development of immunotherapies based on the transduction of NK cells with CAR (chimeric antigen receptor) constructs for the treatment of cancer. Despite the advantages of CAR-NK therapy over CAR-T, including their inability to cause graft-versus-host disease in allogenic therapies, a deeper understanding of the impact of their handling is needed in order to increase their functionality and applicability. With that in mind, the present work critically examines the steps required for NK cell isolation, expansion and storage, and analyze the response of the NK cells to these manipulations. The results show that magnetic-assisted cell sorting, traditionally used for NK isolation, increases the CD16+ population of NK cultures only if the protocol includes both, antibody incubation and passage through the isolation column. Furthermore, based on the importance of surface potential on cellular responses, the influence of surfaces with different net surface charge on NK cells has been evaluated, showing that NK cells displayed higher proliferation rates on charged surfaces than on non-charged ones. The present work highlights the relevance of NK cells manipulation for improving the applicability and effectiveness of NK cell-based therapies.

Keywords: CAR-NK; NK; biomaterials; immunotherapy; natural killer cells; surface potential.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • Cell Membrane
  • Cell Separation
  • Cell- and Tissue-Based Therapy
  • Killer Cells, Natural*
  • Receptors, Chimeric Antigen*

Substances

  • Antibodies
  • Receptors, Chimeric Antigen

Grants and funding

This work was supported by the Basque Government Health Department (Grants 2019111068, 2020111058, 2020333032 and 2021333012) and Economic Development and Infrastructures Department (KK-2020/00068), EITB Maratoia (BIO21/COV/030), Instituto de Salud Carlos III and co-funded by European Union (ERDF) “A way to make Europe” (projects PI18/01299 and PI21/01187), Instituto de Salud Carlos III and co-funded by European Union (NextGenerationEU, ICI21/00095), RICORS: (RD21/00017/0024) Red Española de Terapias Avanzadas TERAV - Instituto de Salud Carlos III, AECC: IDEAS222909EGUI, Red de Inmunoterapia del Cancer “REINCA” (RED2022-134831-T) funded by the Spanish Ministry of Science and Innovation (PID2019-106099RB-C43/AEI/10.13039/501100011033) and from the Basque Government Education Department under the IKUR strategy. S.M.I. was supported by the Jesus Gangoiti Barrera Foundation and by a scholarship of the Basque Government. L.H. was supported by the Jesus Gangoiti Barrera Foundation, “Asociación Española contra el Cáncer” (AECC) and Fundación Mutua Madrileña (AP176182020).